Interleukin-34 cancels anti-tumor immunity by PARP inhibitor.

Takayoshi Nakamura,Nabeel Kajihara,Naoki Hama,Takuto Kobayashi,Ryo Otsuka,Nanumi Han,Haruka Wada,Yoshinori Hasegawa,Nao Suzuki,Ken-Ichiro Seino

Journal of gynecologic oncology（2022）

引用 2|浏览5

暂无评分

摘要

These results suggest that tumor-derived IL-34 benefits tumors by creating an immunosuppressive TME and conferring PARP inhibitor therapeutic resistance. Thus, we showed the pathological effect of IL-34 and the need for it as a therapeutic target in ovarian cancer.

查看译文

关键词

BRCA1-Associated Cancer,CD8 T Cell,Interleukin-34,PARP Inhibitor,Therapeutic Resistance,XCR1 Dendritic Cell

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要